Navigation Links
Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
Date:1/6/2009

PARSIPPANY, N.J., Jan. 6 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, announced today that enrollment has been completed in two pivotal Phase III SIMPLE trials to evaluate the safety and efficacy of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) for prolonged postoperative analgesia.

Results from the studies in hemorrhoidectomy and in total knee arthroplasty (TKA) are expected to provide the primary clinical data, in addition to extensive existing preclinical and clinical data, for a planned 2009 NDA filing under U.S. Food and Drug Administration 505 (b)(2) regulations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

EXPAREL, a proprietary product from Pacira Pharmaceuticals, is a novel long-acting, sustained-release formulation of bupivacaine, a local anesthetic widely used for treating postoperative pain. EXPAREL is being studied in several different types of surgical procedures where postoperative pain management is especially problematic and where the need for prolonged analgesia with a single intraoperative administration can provide a significant improvement in pain relief -- especially during the first 72-hours following surgery -- while also minimizing the need for opioids. With improved prolonged postoperative pain management and a reduction in opioid consumption, Pacira believes patients treated with EXPAREL will experience better pain management and have fewer opioid-related side effects such as nausea and vomiting, and improved outcomes overall.

Recently, Pacira reported the results of a Phase II TKA study of EXPAREL at the International College of Surgeons meeting in Vienna, Austria. The data showed the new sustained-release analgesic significantly reduced postoperative pain, opioid use, and reduced opioid-related adverse events compared to the gold standard pain medication.

Pacira is seeking a co-promotion partner for EXPAREL in the United States. Outside the United States (except Japan), EXPAREL is available for licensing in both human and animal health applications. In the United States, Pacira intends to commercialize EXPAREL and its proprietary pipeline products within specialty acute care. Partnerships in the U.S. for both human and animal health to expand the commercialization are currently in development. EXPAREL is the latest product to benefit from Pacira's proprietary sustained-release DepoFoam(R) technology. DepoFoam technology is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. It achieves this by encapsulating the drug in multivesicular liposomal particles which then release the drug over a desired period of time without altering the drug molecule. DepoFoam is a proven technology that is already used in two commercially available products in the U.S. and Europe.

About Pacira

Pacira Pharmaceuticals, Inc. is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of the acute care market. The company's most advanced product, EXPAREL(TM) (DepoBupivacaine), a bupivacaine-based product intended to deliver postoperative pain relief by infiltration, is in late Phase III clinical development. Pacira also plans to study EXPAREL for nerve block, non-surgical pain such as long bone fracture and for intraarticular injection. EXPAREL benefits from the proprietary DepoFoam Technology owned by Pacira. Two other DepoFoam-based products -- DepoDur(R) and DepoCyt/DepoCyte(R) -- are marketed by partners in several global territories. The DepoFoam technology also forms the basis of multiple development projects providing Pacira an opportunity to expand its pipeline. Pacira owns two cGMP production facilities which produce the two approved products, EXPAREL clinical development and all pipeline materials.

Additional information about Pacira is available at http://www.pacira.com.

This news release contains forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company's clinical trial programs and the preliminary results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward- looking statements contained in the release and anticipated presentation.

Pacira Contact: Taunia Markvicka

Vice President, Commercial Development

973-254-3565


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... KONG , May 24, 2016 /PRNewswire/ ... COMBO ™ , la première ... des cathéters destinés à l,intervention portant sur ... (FAV)   OrbusNeich, entreprise mondiale ... permettant de changer la vie, a élargi ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help ... on a global scale. Medical professionals from Europe ... and the US have already signed up for the app, which ... secure environment. Education  "Imagine a doctor for ... surgeon at Harvard to treat a bomb victim via live streaming ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... Dr. LeRoy Perry’s ... the impact of mobile devices on the billions of users, hundreds of millions of ... While not life threatening, the frequent and common action of looking down at ...
(Date:5/26/2016)... ... May 26, 2016 , ... In Madeira Beach Florida, ... by a single drawbridge, citizens formed an organization, Madeira Beach United, to oppose two ... change the small town center to a high rise urban environment. , According to ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... HealthPostures, ergonomics ... Angle chair , furniture that may support women during pregnancy. Potential benefits of using ... feet, improved rest and comfort and healthier levels of sitting and standing. , Need ...
(Date:5/25/2016)... , ... May 25, 2016 ... ... the American Heart Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus ... This achievement, a second for Memorial Healthcare System, recognizes its commitment to ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... has produced another video highlighting one of the many supplemental program options offered ... Ed Taylor, a 5 th Degree Black Belt in the Shorin-ryu style of ...
Breaking Medicine News(10 mins):